JD Health (06618) has recently entered into a deep collaboration with the domestic innovative pharmaceutical company KGI Chengxin Biotechnology Co., Ltd. (KGI Chengxin). The partnership will leverage JD Health's strengths in medical services and instant retail to support the goal of achieving clinical cures for Chinese patients with chronic hepatitis B.
Simultaneously, KGI Chengxin's Prafovir Mesylate Tablets (brand name: Xin Shu Mu®), a Class 1 innovative drug for chronic hepatitis B and the world's first to utilize HepDirectTM liver-targeting technology, and its Zinc Selenium Multivitamin Softgels (brand name: Kai Mu Mu®), designed to supplement liver nutrition, are being launched exclusively on JD Health's platform. This initiative aims to provide more precise and convenient full-chain services for chronic hepatitis B patients and individuals seeking liver health protection.
The Prafovir Mesylate Tablets (Xin Shu Mu®), now available, are indicated for the treatment of chronic hepatitis B in adults. This drug received continuous support from the National "Twelfth Five-Year Plan" and "Thirteenth Five-Year Plan" Major New Drug Discovery scientific initiatives. It delivers the active drug directly to the liver, enhancing efficacy while reducing toxicity.
Phase III clinical trial results demonstrated that the treatment group achieved stronger and more sustained viral suppression. The reduction in HBsAg levels and the proportion of patients achieving HBsAg levels below 1000 IU/mL were significantly superior to the control group (P<0.05) and outperformed comparable drugs. Notably, unlike similar medications, this drug is not affected by food intake, making administration more convenient.
The Zinc Selenium Multivitamin Softgels (Kai Mu Mu®) are specifically formulated for liver nutrition and are suitable for individuals needing supplementation of zinc, selenium, and various vitamins. The product is rich in nine vitamins—A, B1, B2, B6, B12, niacinamide, C, K, and E—and two minerals, zinc and selenium, with a scientifically validated clinical ratio. Utilizing soy lecithin capsules helps preserve freshness and enhances absorption.
JD Health will fully utilize its ecosystem advantages of "online consultation + pharmaceutical retail + instant delivery" to rapidly popularize these two new drugs. Through an integrated service model combining professional supply, specialist online guidance, and rapid delivery, it aims to provide better options for relevant patients.
Starting immediately, patients can purchase these new drugs through the JD app or JD Pharmacy stores nationwide with a valid prescription. Subsequently, JD Health and KGI Chengxin will integrate their core strengths to deepen strategic synergy, jointly optimize the patient service experience across the entire journey, and enhance the overall efficiency and quality of the pharmaceutical supply chain.
A representative from JD Health stated that the company is committed to providing consumers with high-quality pharmaceutical and health products and services. The collaboration with KGI Chengxin will leverage both parties' capabilities to ensure rapid access to innovative drugs like Prafovir Mesylate Tablets and Zinc Selenium Multivitamin Softgels for a broader patient base.
In recent years, the value of JD Health as the "primary launch platform for novel and specialty drugs" has continued to grow. A significant number of cutting-edge innovative drugs have reached a wide patient base through JD Health's online-offline integrated channels, including its DTP pharmacies, helping patients access more precise, efficient, and improved treatment solutions.
Moving forward, JD Health will collaborate with global pharmaceutical partners to enhance the accessibility of novel and specialty drugs, contributing further to the strategic objectives of "Healthy China 2030."
Comments